Meeting Newsroom

FDA Approves Ziftomenib for Patients With Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia
The FDA approved ziftomenib, a menin inhibitor, for patients with relapsed/refractory acute myeloid leukemia who have an NPM1 mutation and have no satisfactory alternative treatment options.
FDA Grants Approval to Tafasitamab for Patients With Relapsed/Refractory Follicular Lymphoma
The US FDA approved tafasitamab with lenalidomide and rituximab for the treatment adults with relapsed/refractory follicular lymphoma.
FDA Approves Linvoseltamab-gcpt for Patients With Relapsed/Refractory Multiple Myeloma
The US FDA approved linvoseltamab-gcpt for the treatment of adults with relapsed/refractory multiple myeloma based on results from the LINKER-MM1 clinical trial.
Back to top